Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 10/20 | 0.64 |
| ▸ | DBF4 | Q9UBU7 | 10/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2885768 | 0.86 | SMN1; SMN2 (0.51) | CDC7DBF4SMN1; SMN2MAPTTRPM8 | |
| SCHEMBL4464882 | 0.83 | CDC7 (0.73) | CDC7DBF4SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL2881465 | 0.80 | CDC7 (0.72) | CDC7DBF4KDM4EALDH1A1LMNA | |
| SCHEMBL290427 | 0.79 | CDC7 (0.57) | CDC7DBF4SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL12034449 | 0.79 | CDC7 (0.69) | CDC7DBF4KDM4EALDH1A1LMNA | |
| SCHEMBL5733147 | 0.79 | CDC7 (1.00) | CDC7DBF4SMN1; SMN2KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL6201525 | 0.79 | CDC7 (0.70) | CDC7DBF4KDM4EALDH1A1LMNA | |
| SCHEMBL455876 | 0.78 | CDC7 (0.62) | CDC7DBF4KDM4EALDH1A1LMNA | |
| SCHEMBL28297258 | 0.77 | CDC7 (0.65) | CDC7DBF4KDM4EALDH1A1LMNA | |
| SCHEMBL28297244 | 0.77 | CDC7 (0.65) | CDC7DBF4SMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3124489-B1 | THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN INC (US) | 2020-07-15 | — | — | EP | disclosed |
| EP-3124489-A1 | THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | Fibrogen, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2016078-B1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN INC (US) | 2016-06-15 | — | — | EP | disclosed |
| EP-2427447-A2 | SMALL MOLECULE INHIBITORS OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | Pike Pharma GmbH (CH) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010128163-A2 | SMALL MOLECULE INHIBITORS OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | PIKE PHARMA GMBH (CH) | 2010-11-11 | — | — | WO | disclosed |
| US-7696223-B2 | [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) | FIBROGEN, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-2016078-A2 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN, INC. (US) | 2009-01-21 | — | — | EP | disclosed |
| US-20080004309-A1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2008-01-03 | — | — | US | disclosed |
| WO-2007115315-A2 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004309-A1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN2 | CDC7 2482/4885DBF4 2072/4885SMN1; SMN2 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.